Leukamenin E, an ent-kaurane diterpenoid, is a novel and potential keratin intermediate filament inhibitor.
Many ent-kaurane diterpenoids exhibit notable antitumor activity in vitro and in vivo, and some have been used as cancer therapeutic agents in China. In this study, we identified a novel molecular target of leukamenin E, an ent-kaurane diterpenoid, using an available whole-cell model in combination with immunofluorescence imaging and mass spectrometry (MS). The cytoskeleton-disrupting drugs cytochalasin B and colchicine caused the depolymerization of microfilaments and the collapse of microtubules and vimentin filaments, respectively, but had little effects on HepG2 and NCI-H1299 cells spreading as well as keratin filament (KF) reassembly, indicating that KFs are involved in cell spreading. Leukamenin E blocked HepG2 and NCI-H1299 cells adhesion/spreading and KF reassembly at subtoxic concentrations, indicating that leukamenin E may target KFs. Moreover, leukamenin E, at 3 μM for 24 h or 10 μM for 3 h, induced massive KF depolymerization in well-spread HepG2 and NCI-H1299 cells treated with/without cytochalasin B and colchicine. MS analysis indicated that leukamenin E could covalently modify amino acid residue(s) in a synthetic peptide based on keratin 1 and keratin 10 sequences, suggesting that covalent modification of the synthetic peptide by leukamenin E caused assembly inhibition or disrupted KF polymerization in HepG2 and NCI-H1299 cells. In addition, acridine orange/ethidium bromide staining and western blotting confirmed that there was no correlation between the KF-disrupting effects and apoptosis or keratin expression. Thus, we propose that leukamenin E is a novel inhibitor of KF assembly, and as such, can serve as a chemical probe of KF functions and a potential molecular target for ent-kaurane diterpenoid-based therapeutics.